Nanoparticle albumin‐bound (nab)‐paclitaxel is active in PD‐1 inhibitor‐naïve RM‐HNSCC and alters immune cells to potentially prime tumor response and reverse resistance to PD‐1 inhibitors. The gene discussed is ALB; the disease is head and neck squamous cell carcinoma.